Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelareorep + FOLFIRI + Bevacizumab in Second-Line Metastatic Colorectal Cancer
NCT07446322Phase 2Recruiting
- Sponsor
- Oncolytics Biotech Inc.
- Start
- Apr 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of pelareorep in colorectal cancer (CRC), sponsored by Oncolytics Biotech Inc.. Started Apr 2026; status: recruiting.
02
Drugs
pelareorep
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07446322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446322.